Actuate Therapeutics, Inc. (ACTU)
Last updated: 2026-10-24 18:26:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Actuate Therapeutics, Inc. (ACTU) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.48, with a market capitalization of $12.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.41 to $7.90. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$12.40M | |
$0.53 | |
$25.55 | |
$0.41 | |
$0.52 | |
253.02K | |
361.32K | |
-- | |
$7.90 | |
$0.41 | |
-- | |
-- |
Actuate Therapeutics, Inc. (ACTU) Latest Closing Stock Price
Actuate Therapeutics, Inc. (ACTU) last closed at $0.52 as of 2026-10-23 23:38:00, unchanged from the previous close of $0.52.
During the latest regular trading session, ACTU traded between $0.41 and $25.55, with a volume of 253.02K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Actuate Therapeutics, Inc. (ACTU) 7-Day Stock Price Change
Over the past seven days, Actuate Therapeutics, Inc. (ACTU) moved from $0.50 to $0.48, representing a decline of 4.38% ($0.02).
The stock traded between $0.43 and $0.71 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 443.43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
ACTU 52-Week Price Position
Position in Range: 0.9%
ACTU is currently trading at $0.48, placing it 0.9% of the way from its 52-week low of $0.41 to its 52-week high of $7.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Actuate Therapeutics, Inc. (ACTU)?
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Actuate Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Actuate Therapeutics, Inc. (ACTU) Stock on MEXC
Eligible investors can buy real shares of Actuate Therapeutics, Inc. (ACTU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Actuate Therapeutics, Inc. (ACTU) stock price today?
2.Is ACTU stock going up or down today?
3.What is ACTU pre-market price?
4.What is ACTU after-hours price?
5.Is ACTU stock trading now?
6.Where does ACTU sit relative to its 52-week high and low?
7.What sector is Actuate Therapeutics, Inc. in?
8.What is Actuate Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is ACTU valued in terms of P/E ratio and EPS?
10.Does Actuate Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
ACTU Stock Calculator
Estimate the value between ACTU shares and USD.
ACTU Shares to USD
1.00 ACTU shares = 0.478 USD
Calculations are estimates based on the latest available price and are for reference only.


